A

Alexion

Global biopharmaceuticals focusing on rare diseases

Regional Account Manager - US HPP

Full-TimeUpdated on 10/23/2026Deadline 11/27/26
$152.6k - $229k/yr+ Short-term incentive bonuses + Equity-based awards + Sales commissions
Senior
Bachelor's, Master's
San Francisco, CA, USA+1 moreMore locations: San Jose, CA, USA
In PersonField-based role; travel 50–60% within the assigned territory, including frequent overnight and some weekend travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • A degree in life science and/or business/marketing is required.
  • A proven, documented track record of delivering consistent top-tier sales results, with a consistent record of success in the top 20% of performance.
  • At least 5 years of pharmaceutical or equivalent experience, such as biotech or medical device experience.
  • Ability to work effectively both independently and collaboratively in a team-oriented environment on a consistent basis.
  • Ability to gain consistent access to healthcare providers in community and academic centers and develop strong professional relationships for scientific exchange and promotion.
  • Demonstrated success in strategic territory management.
  • Effective verbal and written communication skills and organizational abilities.
  • Valid driver's license and clean driving record.
  • Ability to travel 50–60% within the assigned territory on a regular basis, including frequent overnight and some weekend travel.
  • Ability to perform the role's field-based duties, including traveling by public transportation, automobile, train, or plane; working comfortably in a clinical setting; using a computer; communicating by phone, video, and electronic messaging; problem-solving; engaging in complex and non-linear thought, analysis, and dialogue; collaborating; and maintaining general availability during standard business hours.
Responsibilities
  • Professionally represent Alexion by educating customers about HPP disease, identifying patients potentially impacted by HPP, increasing visibility of disease-awareness initiatives, and supporting customer satisfaction in the territory.
  • Implement disease-awareness, diagnostic, and branded sales and marketing programs.
  • Maintain effective communication and relationships with key external and internal customers.
  • Consistently achieve or exceed sales objectives in the assigned territory.
  • Develop and maintain in-depth knowledge of the product, market, and customers.
  • Develop and implement strategically targeted account-specific territory business plans aligned with corporate strategy and informed by local market forces affecting product sales.
  • Manage the territory and analyze market dynamics to meet sales goals; update business plans accordingly.
  • Develop and maintain strong clinical, technical, and scientific knowledge.
  • Seek out and qualify leads and profile new accounts.
  • Educate customers on the diagnostic approach to the disease, supporting differential diagnosis and appropriate testing of patient populations.
  • Use marketing tools and resources appropriately, including PowerPoint presentations.
  • Lead implementation of the patient-centric partnership model in the assigned territory, engaging physicians, their staff, clinics, and hospitals, and provide product expertise and customer service to accounts.
  • Make compelling and persuasive sales calls to designated customers to generate sales of Alexion products.
  • Collaborate closely with stakeholders, including TLLs, SALs, MSLs, FRMs, Market Access, Diagnostics, and other enterprise partners.
  • Proactively interact with Alexion management to refine product and market initiatives.
  • Manage time, priorities, the customer relationship management (CRM) tool, resources, and workload effectively and efficiently.
  • Manage administrative responsibilities and submit accurate, timely reports on sales activities.
  • Perform work in alignment with and adhere to Alexion's Code of Ethics and Business Conduct and its policies and procedures.
Desired Qualifications
  • An advanced or master's degree is preferred.
  • Biopharma experience is preferred.
  • Top-tier awards, such as a President's Club Award, are preferred.
  • Sales experience in endocrinology or medical genetics specialties, or experience selling to physicians specializing in bone disorders, is strongly preferred.
  • Experience selling enzyme replacement therapy products is strongly preferred.
  • Experience in orphan, ultra-orphan, or rare diseases is strongly preferred.
  • Sales experience in nephrology, orthopedic surgery, or rheumatology specialties is strongly preferred.
  • Experience with self-injected products is strongly preferred.
  • Institutional or academic-center account experience is preferred.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old